LONDON–(BUSINESS WIRE)–Citi, acting through Citibank N.A., has been appointed by Mereo
BioPharma Group plc (“Mereo”) as depositary bank for its American
Depositary Receipt (“ADR”) programme following the merger between Mereo
and OncoMed Pharmaceuticals, Inc., pursuant to which OncoMed will become
a wholly-owned indirect subsidiary of Mereo. Mereo’s ADRs trade on the
Nasdaq Global Market under the symbol “MREO.” Each ADR represents five
ordinary shares of Mereo. Mereo’s underlying ordinary shares are listed
and trade on the London Stock Exchange AIM market under the symbol “MPH”.
“Citi is delighted to be appointed by Mereo as depositary bank for its
Nasdaq listed ADR programme,” said Dirk Jones, Global Head of Issuer
Services, at Citi. “We are confident that we will be able to assist
Mereo in expanding their investor outreach through the support of our
leading investor relations advisory team and our global equity
distribution network.”
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
About Mereo
Mereo is a biopharmaceutical company focused on
the development and commercialisation of innovative therapeutics that
aim to improve outcomes for patients with rare diseases. Mereo’s
strategy is to selectively acquire product candidates that have
substantial preclinical, clinical and manufacturing data packages.
Mereo’s four product candidates have previously generated positive
clinical data for Mereo’s target indications or in related indications.
Mereo has commenced randomised Phase 2 clinical trials for all four of
the product candidates. In connection with the merger with OncoMed,
Mereo added two candidates to its pipeline, Navicixizumb and Etigilimab.
-
BPS-804 for osteogenesis imperfecta (OI). In October 2018, the Company
announced completion of enrollment of 112 adult patients in a Phase 2b
dose ranging study with initial data expected in Q2 2019 and top-line
dose ranging data in late 2019. A pediatric Phase 3 study design has
also been approved by the EMA. BPS-804 has orphan designation in the
U.S. and the EU and has been accepted into the PRIME and Adaptive
Pathways in EU; -
MPH-966 for alpha-1 antitrypsin deficiency (AATD). The Company
recently announced dosing of the first patient in a Phase 2 dose
ranging study in the U.S. with data expected around the end of 2019; -
BCT-197 for severe exacerbations of COPD. The Company announced
positive Phase 2 data in May 2018 and recently announced the outline
of the pivotal Phase 3 study including the primary and key secondary
endpoints following the successful end of Phase 2 Type B meeting with
the FDA; -
BGS-649 for hypogonadotropic hypogonadism (HH). The Company announced
positive top-line Phase 2b data in March 2018 and positive results
from the Phase 2b safety extension study in December 2018; -
Navicixizumab has completed a Phase 1a single-agent clinical trial in
patients with advanced solid tumors and is currently in a Phase 1b
trial in combination with a standard paclitaxel regimen in patients
with platinum-resistant ovarian cancer. This study recently completed
enrolment; and -
Etigilimab has completed a single-agent Phase 1a trial in patients
with advanced or metastatic solid tumors and is currently in a Phase
1b combination study with nivolumab. Etigilimab is part of OncoMed’s
prior collaboration with Celgene. Celgene has the option to obtain an
exclusive licence to develop and commercialize the product. If Celgene
exercises such option, OncoMed (now a wholly-owned indirect subsidiary
of Mereo) will be eligible to receive a $35 million opt in payment.
About Citi
Citi, the leading global bank, has approximately
200 million customer accounts and does business in more than 160
countries and jurisdictions. Citi provides consumers, corporations,
governments and institutions with a broad range of financial products
and services, including consumer banking and credit, corporate and
investment banking, securities brokerage, transaction services, and
wealth management.
Additional information may be found at www.citigroup.com
| Twitter: @Citi | YouTube: www.youtube.com/citi
| Blog: http://blog.citigroup.com
| Facebook: www.facebook.com/citi
| LinkedIn: www.linkedin.com/company/citi
Contacts
Citi Media Contacts:
Capucine Boncenne
+44 (0) 20 7508
9355
capucine.boncenne@citi.com
Mereo
Investor Contacts:
Richard Jones, CFO
+44 (0)333
023 7319
rj@mereobiopharma.com
Burns
McClellan (US Public Relations Adviser to Mereo):
Jill Steier
+01
(0) 212 213 0006
Jsteier@burnsmc.com